The effect of Chronic treatments of Type 2diabetes mellitus on COVID-19 Morbidity and Symptoms Severity
Rozalia Mamari, Key=rama Ibrahim, Ibrahim Rama, Syria Latakia
doi:10.52711/0974-360X.2023.00831(
Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease that causes the severe acute respiratory syndrome (SARS), and has had a disastrous impact on demographics around the world. Studies have classified type 2-diabetes mellitus (T2DM) as a risk factor for increasing mortality and se-verity of disease symptoms. However, the effect of different T2DMchronic medications on disease progression is still unclear. The aim of this study was to determine the effect of glycemic control on COVID-19-related mortality and symptom severity, as well as the impact of commonly used T2DM therapeutic approaches on disease outcomes. This study included 109 COVID-19 patients with (68 patients) or without (41 patients) type 2-diabetes mellitus. Diabetic patients were further classified according to: 1) their glycemic control [HbA1c levels ˂6.5% (Well-controlled) and ≥ 6.5% (Less-controlled)], or 2) their pre-hospital anti-hyperglycemic med-ication [metformin (50%) or sulfonylureas (50%)]. Our results showed that diabetes is associated with a significantly higher risk of death in COVID-19 pa-tients. We also found that metformin treatment reduces plasma C-reactive protein levels and mortality Compared with sulfonylureas, and continuing with metformin during the hospital stay had a better prog-nostic for survival. We also, demonstrated that taking sulfonylurea is associated with an increase in COVID-19 mortality as compared to metformin by increasing cardiovascular events.
CONFLICT OF INTEREST: The authors have no conflicts of interest regarding this investigation.
References
Amin, Lux, 'callaghan, The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth, Br J Clin Pharmacol,
doi:10.1111/bcp.13780Association, Glycemic Targets: Standards of Medical Care in Diabetes-2021, Diabetes Care,
doi:10.2337/dc21-S006Ayoub, Fatima, Kaushik, Pulmonary Aerosolized Formulation or Nasal Drops containing Recombinant Human Angiotensin converting Enzyme 2 (rhACE2) as a Potential Therapy against COVID-19, Research Journal of Pharmacy and Technology,
doi:10.52711/0974-360X.2021.00597Bode, Garrett, Messler, Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States, J Diabetes Sci Technol,
doi:10.1177/1932296820924469Dawood, Altobje, Alnori, Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins, Research Journal of Pharmacy and Technology,
doi:10.52711/0974-360X.2021.00828Elnaem, Cheema, Caring for patients with diabetes during COVID-19 pandemic: Important considerations for pharmacists, Res Soc Adm Pharm,
doi:10.1016/j.sapharm.2020.05.030Gabir, Hanson, Dabelea, The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes, Diabetes Care,
doi:10.2337/diacare.23.8.1108Hariyanto, Kurniawan, Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection, Obes Med,
doi:10.1016/j.obmed.2020.100290Herman-Edelstein, Guetta, Barnea, Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system, Cardiovasc Diabetol,
doi:10.1186/s12933-021-01275-wHoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Kondody, Varma, Patil, Cytokine Storm, Immunomodulators and Mucormycosis in COVID-19: Bench To Bed Side, Research Journal of Pharmacy and Technology,
doi:10.52711/0974-360X.2022.00818Krysiak, Gdula-Dymek, Okopieñ, Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance, Pharmacol Rep,
doi:10.1016/s1734-1140(13)71489-0Kumar, Arora, Sharma, Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.04.044Menon, Bhagat, Review of the impact Covid-19 has on the Psychosocial factors affecting Well-Being, Research Journal of Pharmacy and Technology,
doi:10.52711/0974-360X.2021.00592Mishra, Pathak, Mohakuda, Relation of D-dimer levels of COVID-19 patients with diabetes mellitus, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.09.035Mor, Saini, Wangnoo, Bawa, Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India, Research Journal of Pharmacy and Technology,
doi:10.5958/0974-360X.2020.00450Patel, Klek, Peragallo-Dittko, Correlation of Hemoglobin A1C and Outcomes in Patients Hospitalized With COVID-19, Endocr Pract,
doi:10.1016/j.eprac.2021.07.008Saber, Khodir, Maghmomeh, Nouh, El-Baz, COVID-19 Pandemic: current Challenges and future Perspectives, Research Journal of Pharmacy and Technology,
doi:10.52711/0974-360X.2022.00054Shaty, Al-Ezzi, Arif, Effect of Metformin on inflammatory markers involved in Cardiotoxicity induced by Doxorubicin, Research Journal of Pharmacy and Technology,
doi:10.5958/0974-360X.2019.01007Toniolo, Cassani, Puggioni, The diabetes pandemic and associated infections: suggestions for clinical microbiology, Rev Med Microbiol,
doi:10.1097/MRM.0000000000000155
